The pharmacological mechanism of ritexitinib

Ritlecitinib is an oral small molecule tyrosine kinase inhibitor (JAK inhibitor) that mainly targets the JAK3 and TEC family kinases. Its pharmacological mechanism interferes with the signal transduction of multiple cytokines by inhibiting the JAK-STAT signaling pathway, thereby regulating the activity of the immune system and reducing inflammatory responses and abnormal proliferation of immune cells.

The JAK-STAT signaling pathway plays a key role in the immune system. Many cytokines transmit signals through the JAK-STAT pathway to regulate the differentiation, proliferation and activation of immune cells. In this process, the JAK (Januskinase) family includes JAK1, JAK2, JAK3 and TYK2 cooperate with different cytokine receptors to phosphorylate STAT (signal transduction and transcriptional activator) after activation, thereby inducing the expression of specific genes.

Ritexitinib reduces specific cytokines (such as IL-2, IL-4, IL-7, IL by selectively inhibiting the activity of JAK3 -9, IL-15 and IL-21)-mediated signaling, inhibiting the proliferation and activation of T cells and NK cells. In addition, ritexitinib can also inhibit TEC family kinases, which play an important role in B cell receptor signaling and bone marrow hematopoiesis. Therefore, through dual inhibition of JAK3 and TEC family kinases, ritexitinib can broadly modulate immune responses.

This mechanism of action of ritexitinib gives it therapeutic potential in a variety of autoimmune diseases. For example, in alopecia areata and other specific inflammatory diseases, ritexitinib can control symptoms and alleviate the disease by reducing the infiltration of inflammatory cells and pathological immune responses. Compared with other non-selective JAK inhibitors, ritexitinib's high selectivity for JAK3 reduces the impact on other JAK family members, which is expected to reduce related adverse reactions and improve its safety and tolerability.

The mechanism of action of ritixitinib gives it unique therapeutic advantages in clinical application, especially in regulating abnormal immune responses and reducing chronic inflammation, providing a new treatment option.